Finally, a very recent work exploring the role of NRF2 in KRAS-driven pancreatic ductal adenocarcinoma (PDAC) tumors, showed that the high levels of NRF2 identified cancers with poorer clinical outcomes characterized by increased resistance to gemcitabine and a marked dependence on glutamine metabolism and cystine uptake. This evidence concerns the gene NFE2L2 and pancreatic ductal adenocarcinoma.